Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study.
Susarla SK, Gupta M, Mantan M, Dhongade R, Bhave S, Das RK, Ray RK, Ramesh Babu T, Ravi MD, Krishnamurthy B, James S, Sandhya G, Satish M, Sahoo DP. Susarla SK, et al. Among authors: sandhya g. Vaccine. 2019 Aug 23;37(36):5452-5459. doi: 10.1016/j.vaccine.2019.06.067. Epub 2019 Jul 19. Vaccine. 2019. PMID: 31331773 Clinical Trial.
Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study.
Susarla SK, Palkar S, Sv PS, Diwan A, Barsode S, Satish M, Rajashakar BC, Sandhya G, Lingala R, Sahoo DP. Susarla SK, et al. Among authors: sandhya g. Vaccine. 2021 Apr 8;39(15):2088-2093. doi: 10.1016/j.vaccine.2021.03.012. Epub 2021 Mar 17. Vaccine. 2021. PMID: 33741190 Clinical Trial.
Immunogenicity and safety of HavisureTM vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
Susarla SK, Gupta M, Uttam KG, Palkar S, Dhongade AR, Siva Ram Prasad K, Rajapantula V, Ravi MD, Pradeep N, Satish M, Rajashakar BC, Sandhya G, Rajendra L, Sahoo DP, Kanakasapapathy AK. Susarla SK, et al. Among authors: sandhya g. Vaccine. 2023 Oct 6;41(42):6215-6220. doi: 10.1016/j.vaccine.2023.08.084. Epub 2023 Sep 1. Vaccine. 2023. PMID: 37661535 Clinical Trial.
Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study.
Krishna Susarla S, Jahagirdar R, Ghosh Uttam K, Srikanth Bhatt S, Prashanth S, Rajapantula V, Satish M, Rajashakar BC, Sandhya G, Rajendra L, Prasad Sahoo D, Kumar Kanakasapapathy A. Krishna Susarla S, et al. Among authors: sandhya g. Vaccine. 2023 Oct 20;41(44):6558-6564. doi: 10.1016/j.vaccine.2023.08.065. Epub 2023 Aug 31. Vaccine. 2023. PMID: 37659893
Assessment of Utilization of Rehabilitation Services among Stroke Survivors.
Mahak C, Shashi, Yashomati, Hemlata, Manisha N, Sandhya G, Dheeraj K, Dhandapani M, Dhandapani SS. Mahak C, et al. Among authors: sandhya g. J Neurosci Rural Pract. 2018 Oct-Dec;9(4):461-467. doi: 10.4103/jnrp.jnrp_25_18. J Neurosci Rural Pract. 2018. PMID: 30271034 Free PMC article.
14 results